Making all naloxone products available OTC in the US could limit, rather than expand, access to the opioid overdose treatment, according to comments submitted before US Food and Drug Administration advisors discuss the first naloxone switch proposal.
The American Society of Anesthesiologists and attorney Scott Lassman both made clear in comments, submitted to the docket for a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?